Medis, strongest independent medical marketing company in the CEE, generated 70% revenues from international markets. Trend expected to continue in 2020.
2019 was an outstanding year for Medis. 70% of revenues was generated from markets outside of Slovenia, significantly exceeding the company’s target. The largest share of the growth came from sales in Austria, Bulgaria, Croatia and Serbia where the company was extremely successful in introducing the most advanced medicines and medical devices to these markets.
The rapid expansion and the introduction of important novel therapeutic options further enhanced the position of Medis as the leading independent company for commercialization of pharmaceutical products with fully-owned subsidiaries across Central and Eastern Europe.
Medis’ revenues grew by 22% from 2018, reaching EUR 120 million at the end of 2019.
“We are proud that through 30 years of continuous focus, innovation, investment and growth we are now able to bring innovative medicines and medical devices to as many as fifteen countries across Central and Eastern Europe. These markets are often not prioritized by renowned pharmaceutical companies due to financial and regulatory entry barriers which are very complex and demanding. That is why they partner with Medis and together we bring novel specialty medicines to the patients of the region”,
said Martina Perharič, CEO of Medis.
With double digit growth over the past years we are proving our dedication to providing the best possible service to both the patients and healthcare systems across all the countries that we are present in.
Summary:
- In 2019 Medis generated 70% of revenues from international markets
- Biggest growth came from Austria, Croatia, Bulgaria and Serbia
- Revenues grew to EUR 120 million – a 22% increase from 2018
- New markets expansion through fully-owned subsidiaries in Slovakia, Lithuania, Latvia and Estonia totalling its presence to 15 countries across Central and Eastern Europe
In 2019, portfolio of well established speciality medicines for treating chronic inflammatory diseases, glaucoma, epilepsy and other neurological diseases was expanded. Besides that, Medis also strengthened its presence in the field of rare diseases, asthma and plasma-derived medicines.
Market Expansion
During 2019, Medis further expanded its presence in CEE with four new EU markets, namely, Slovakia, Lithuania, Latvia and Estonia. This expansion now brings a total number of Medis’ subsidiaries operating in 15 different markets and reaching as far as Tallinn and Sofia.
